Lut Ming Cheng
JPMorgan Chase & Co, Research Division
Good afternoon. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Absci.
I will now pass the mic to their CEO, Sean McClain for a short presentation, followed by a live audience Q&A. Sean, welcome. The stage is yours.
Sean McClain
Founder, CEO, President & Director
Thank you, Brian. As Brian said, I’m Sean McClain, the Founder and CEO of Absci. We’re a generative AI drug creation company, and we’re entering this really exciting new era where we’re actually seeing the molecules that we designed in our AI, not only go into the clinic, but actually start to see proof of concept. Within the next 24 months, we will have two Phase II readouts in androgenic alopecia as well as endometriosis.
We’re looking to industrialize AI for drug discovery. We want to be able to leverage AI to figure out what biology we should be going after, what molecules we should be designing and this is all occurring through our wet lab in the loop. Today, we announced a brand-new model, Origin-1 that was released. And the progress we’ve been making on the AI has been because of this wet lab in the loop that you see here on the right. The 6-week cycle time that we have, we were able to rapidly validate our models with real-world data. And again, this is allowing us to make decisions as to which biology we
